Overview of MicroRNAs in Cardiac Hypertrophy, Fibrosis, and Apoptosis

Juan Wang 1,2, Oi Wah Liew 1,2, Arthur Mark Richards 1,2,3,4 and Yei-Tsung Chen 1,2,*

1 Cardiovascular Research Institute, National University Health System, Singapore 119228, Singapore; mdcwaju@nus.edu.sg (J.W.); mdclow@nus.edu.sg (O.W.L.); arthur_mark_richards@nuhs.edu.sg (A.M.R.)
2 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore
3 Cardiac Department, National University Health System, Singapore 119228, Singapore
4 Christchurch Heart Institute, University of Otago, Christchurch 8014, New Zealand
* Correspondence: mdccyt@nus.edu.sg; Tel.: +65-9238-4561; Fax: +65-6775-9715

Academic Editor: William Chi-shing Cho
Received: 21 March 2016; Accepted: 7 May 2016; Published: 18 May 2016

Abstract: MicroRNAs (miRNAs) are non-coding RNAs that play essential roles in modulating the gene expression in almost all biological events. In the past decade, the involvement of miRNAs in various cardiovascular disorders has been explored in numerous in vitro and in vivo studies. In this paper, studies focused upon the discovery of miRNAs, their target genes, and functionality are reviewed. The selected miRNAs discussed herein have regulatory effects on target gene expression as demonstrated by miRNA/3′ end untranslated region (3′UTR) interaction assay and/or gain/loss-of-function approaches. The listed miRNA entities are categorized according to the biological relevance of their target genes in relation to three cardiovascular pathologies, namely cardiac hypertrophy, fibrosis, and apoptosis. Furthermore, comparison across 86 studies identified several candidate miRNAs that might be of particular importance in the ontogenesis of cardiovascular diseases as they modulate the expression of clusters of target genes involved in the progression of multiple adverse cardiovascular events. This review illustrates the involvement of miRNAs in diverse biological signaling pathways and provides an overview of current understanding of, and progress of research into, of the roles of miRNAs in cardiovascular health and disease.

Keywords: microRNA; hypertrophy; fibrosis; apoptosis

1. Introduction

MicroRNAs (miRNAs) are small non-coding RNAs that have emerged as essential regulators for almost all aspects of intracellular signaling pathways in eukaryotic cells. MiRNAs originate from long primary transcripts (pri-miRNA) and are subsequently cleaved by the nuclear ribonuclease, Drosha, to form microRNA precursors (pre-miRNA) of approximately 70-nucleotides. Pre-miRNAs are exported to the cytoplasm and further processed into approximately 22-nucleotide double-stranded miRNAs by the endonuclease, Dicer. One of the strands, namely the guide strand or mature miRNA, binds to Argonaute proteins within the RNA-induced silencing complex (RISC). The RISC utilizes the guide strand to target the 3′ end untranslated regions (3′UTR) of gene transcripts by Watson-Crick base pairing. The action of miRNAs usually results in downregulation of their target genes by triggering messenger RNA degradation or by inhibiting the translational machinery [1]. The importance of miRNAs in the cardiovascular system is demonstrated by the profound structural and functional abnormalities observed in cardiac-specific Dicer deletion in animal models [2–4]. For the past decade, studies using various cellular and animal disease and transgenic models have allowed identification of miRNAs and their target genes, in various cardiovascular disease states.
By definition, cardiac remodeling is a dynamic and adaptive process in the normal state (physiological remodeling) or in the course of disease progression (pathological remodeling) where the heart alters its structure to regain hemodynamic homeostasis against mechanical stretch or extrinsic stimulation by neurohormones or cytokines. In the diseased state, however, pathological cardiac remodeling is often triggered by conditions that lead to pressure or volume overload, such as myocardial infarction, valve stenosis or regurgitation, hypertension, myocarditis, and a broad range of familial and acquired cardiomyopathies [5]. Neurohormonal derangement such as prolonged stimulation from over-activated renin-angiotensin-aldosterone (RAAS) and sympathetic nervous (SNS) systems are triggered by cardiac injury and/or overload and also contribute directly to adverse cardiac remodeling. The mechanisms of pathological cardiac remodeling involve complex cellular and molecular signaling cascades that regulate myocyte growth, hypertrophy, cardiac fibrosis, necrosis, apoptosis, electrical conduction, and metabolic homeostasis. To date, the involvement of miRNAs in cardiac dysfunction are best characterized in hypertrophy, fibrosis, and apoptosis.

The roles of miRNAs in regulating the expression of genes related to cardiovascular diseases have been investigated in numerous cellular and animal models and have been reviewed extensively [6–8]. However, validation of specific miRNA target genes and identification of the affected signaling pathways have not yet been extensively completed and discussed. Identification of target mRNAs for specific miRNAs is the crucial first step for elucidating the physiological functions of miRNAs. Since most miRNAs are only partially complementary to their target sites, in silico prediction on the basis of sequence homology alone is not sufficient for identifying miRNA targets in real biological systems. Experimental validation is required in determining physiologically relevant gene targets. In this review, the regulatory effects of microRNAs in cardiac remodeling, particularly cardiac hypertrophy, fibrosis, and apoptosis are reviewed. Modulation of the expression of target genes by the miRNAs selected for this review has been demonstrated by miRNA/3’UTR mRNA interaction assays, and/or by gain- or loss-of-function assays in cardiac-derived cell lineages.

2. Hypertrophy-Related miRNAs

Biomechanical stress and other pathological stimuli potentially trigger cardiac remodeling manifested as cardiac hypertrophy with an increase in myocyte size and myofibrillar volume, but not myocyte cell number facilitating sustained cardiac output in the face of functional insult. However, whilst such an adaptive mechanism is beneficial in the short term, prolonged hypertrophy has potentially disastrous consequences leading ultimately to heart failure and death. Studies profiling dysregulated miRNA expression in animal models of cardiac hypertrophy induced by thoracic-aortic banding or via constitutively activated calcineurin signaling have revealed both up- and down-regulated miRNAs. Functional analyses of these dysregulated miRNAs have demonstrated that miRNAs may exert either positive or negative regulatory effects on cardiac hypertrophic pathways.

The role of one of the most abundant cardiac miRNAs, miR-1, in hypertrophy was suggested by the inverse relationship between its expression and progression of cardiac hypertrophy in a transverse aortic constriction (TAC) rodent model. Gain-of-function miRNA studies in neonatal myocyte culture demonstrated downregulation of several hypertrophic target genes of miR-1 predicted in silico, including Ras GTPase-activating protein (RasGAP), cyclin-dependent kinase 9 (Cdk9), Ras homolog enriched in brain (Rheb), and fibronectin [9]. Further studies demonstrate that miR-1 prevents cardiac hypertrophy by suppressing heart and neural crest derivatives expressed 2 (Hand2), and by inhibiting the activity of insulin-like growth factor (Igf1) and extracellular matrix remodeling factor, twinfilin 1 (Twf1) [10,11]. miR-101 was shown to regulate the expression of ras-related protein-1A (Rab1A) in the TAC-induced hypertrophy rodent model and in angiotensin II induced cellular hypertrophy. Antagonism of miR-101 attenuated the hypertrophic phenotype in both models [12]. The role of miR-133 in regulating cardiac hypertrophy was demonstrated by the induction of cardiac hypertrophy in miR-133 null mice. Molecular investigations revealed that miR-133 targets multiple anti-hypertrophic genes, including guanosine triphosphate-guanosine diphosphate (GDP-GTP)
exchange protein, Rhoa, signal transduction kinase cell division control protein 42 (Cdc42), and the nuclear factor, negative elongation factor complex member A (Nelfa/Whsc2) [13]. miR-145 negatively regulates the expression of GATA binding protein 6 (GATA6) and subsequently attenuates hypertrophy in isoproterenol-induced cellular hypertrophy models [14]. Cardiomyocyte hypertrophy induced by high glucose is modulated by miR-150 via its regulatory effect on the expression of the transcriptional co-activator, p300 [15]. Downregulation of miR-185 in a TAC-induced hypertrophy rodent model was found to produce anti-hypertrophic effects by targeting multiple genes in calcium signaling pathways, including calcium/calmodulin-dependent protein kinase II δ (Camk2d), sodium/calcium exchanger 1 (Ncx1), nuclear factor of activated T cells, cytoplasmic, and calcineurin dependent 3 (Nfatc3). miR-185 also attenuates endothelin 1-induced hypertrophy in neonatal rat myocytes, as evidenced by reductions in cellular size and expression of hypertrophic markers [16]. miR-223 antagonizes hypertrophy, induced by endothelin-1 or TAC, through targeting of cardiac troponin I (cTnI)-interacting kinase (Tnmi3k) [17]. In murine models, miR-26 inhibits expression of its predicted target gene, GATA4, in TAC-induced mouse cardiac hypertrophy [18]. Similarly, down-regulation of miR-34a was observed in angiotensin II-induced hypertrophy in myocardial cells resulting in upregulation of the expression of an autophagy related gene, Agt9a [19]. Another anti-hypertrophic miRNA, miR-378, controls cardiac hypertrophy in the TAC model via repression of mitogen activated protein kinase (MAPK) signaling by targeting Mapk1, insulin-like growth factor receptor 1 (Igf1r), growth factor receptor-bound protein 2 (Grb2), and kinase suppressor of ras 1 (Ksr1) [20]. miR-9 opposes cardiac hypertrophy by targeting myocardin and reducing expression of nuclear factor of activated T cells c3 (Nfatc3). Overexpression of miR-9 suppresses cardiac hypertrophy in animal models [21]. Similarly, miR-98 was demonstrated to be an anti-hypertrophic miRNA by targeting Cyclin D2 [22].

In contrast, other miRNAs are pro-hypertrophic. For instance, miR-155 has been reported to play a role in hypertrophy and cardiac remodeling by targeting tumor protein p53-induced nuclear protein (Tp53inp1) [23]. The miR-19a/b family directly targets the anti-hypertrophic genes atrogin 1 and muscle ring finger protein 1 (Murf1) with subsequent activation of calcineurin/nuclear factor of activated T cells (NFAT) signaling. Overexpression of miR-19a/b induces hypertrophy in rat neonatal cardiomyocytes [24]. miR-199a impairs autophagy and induces cardiac hypertrophy through activation of mTOR signaling [25,26]. miR-199b plays an important role in the activation of calcineurin/NFAT signaling by targeting Nfat kinase dual-specificity tyrosin-(Y)-phosphorylation regulated kinase 1a (Dyrk1a). Antagonism of miR-199b in a mouse heart failure model significantly suppressed the progression of cardiac hypertrophy and fibrosis [27]. Another cluster of miRNAs, namely miR-208a and miR-208b are known to be pro-hypertrophic through targeting of negative regulators of hypertrophy including thyroid hormone-associated protein 1 (Thrap1) and myostatin 2 [28]. Furthermore, one of the most well-known cardiovascular disease related miRNAs, miR-21, is thought to target phosphatase and tensin homolog (Pten) and subsequently modulate the activation of the AKT/mTOR pathway, resulting in hypertrophy and fibrosis [29]. Interestingly, its passenger strand, miR-21-3p also exerts hypertrophic effects by targeting histone deacetylase-8 (Hdac8), sorbin and SH3 domain-containing protein 2 (Sorbs2), and PDZ-LIM domain 5 (Pdlim5) [30,31]. By targeting the anti-hypertrophic Forkhead box O3 (Foxo3) transcription factor, miR-212/132 and miR-23a activate pro-hypertrophic calcineurin/NFAT signaling [32,33]. miR-23a may also regulate the expression of lysophosphatidic acid receptor 1 (Lpa1) and induce cardiomyocyte hypertrophy [34]. Several studies support a role for miR-22 in cardiac hypertrophy via targeting Pten, Sirtuin 1 (Sirt1), and histone deacetylase 4 (Hdac4) as evidenced by results from transgenic mouse models and multiple induced-hypertrophic cellular platforms [35–37]. miR-221 is thought to play a role in the development of cardiac hypertrophy in heart disease via targeting of cyclin-dependent kinase inhibitor 1B (p27) [17]. miR-27b targets the anti-hypertrophic transcription factor, peroxisome proliferator-activated receptor γ (Pparγ) [38]. Cardiac hypertrophy induced by angiotensin II both in vitro and in vivo, is mediated by downregulation of beclin 1 by miR-30a [39]. The passenger strand, miR-30a-3p is also involved in autophagy and cardiac hypertrophy via targeting of X-box binding protein 1 (Xbp1), a stress response transcription factor [40]. In an animal
model of pressure overload, the expression of the key calcium-transporting ATPase responsible for Ca\(^{2+}\) re-uptake, Sarco/endoplasmic reticulum Ca\(^{2+}\)-ATPase 2a (ATP2a2, also known as Serca2a), is targeted by miR-328 and subsequently resulting in activation of calcineurin/NFAT signaling, one of the signature pathways leading to hypertrophy [41]. In the rat TAC-induced hypertrophic model miR-350 targets Mapk11/14 and Mapk8/9. Upregulation of miR-350 attenuated the inhibitory effect exerted by p38 and Jun amino-terminal kinases (JNK) pathways on calcineurin/NFAT signaling leading to cardiomyocyte hypertrophy and apoptosis [42]. Figure 1 illustrates the interactions between known miRNAs in three classical hypertrophic signaling pathways, namely phosphatidylinositol 3 monophosphate-dependent protein kinase G (cGMP-PKG).

Figure 1. MicroRNAs (miRNAs) in cardiac hypertrophic pathways. MiRNAs regulate cardiac hypertrophy by targeting key components in three Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways (PI3K-AKT, MAPK, and cGMP-PKG). MiRNAs colored in blue indicate anti-hypertrophic function, miRNAs colored in purple indicate pro-hypertrophic function. Igf1, insulin-like growth factor 1; Gfs, growth factors; NPs, natriuretic peptides; Igfr1, Insulin-like growth factor 1 receptor; RTK, receptor tyrosine kinases; NPRs, natriuretic peptide receptors; PI3K, phosphatidylinositol 3 kinase; Pten, phosphatase and tensin homolog; AKT, protein kinase B; Gsk3\(\beta\), glycogen synthase kinase 3 \(\beta\); p300, E1A binding protein p300; Foxo3, Forkhead box O 3; Sirt1, Sir2 family member A; CCND1, Cyclin D1; CCND2, Cyclin D2; Ras, small G-protein; Grn2, growth factor receptor-binding protein 2; Rab1x, Ras-related protein Rab 1 x; RafB/Raf1, B-Raf proto-oncogene serine/threonine-protein kinase; Cdc42, cell division cycle 42; Mapk1, Mitogen-activated protein kinase 1; Mapk11/14, mitogen-activated protein kinase 11/14; Mapk 8/9, mitogen-activated protein kinase 8/9; p53, tumor protein p53; c-Fos, proto-oncogene protein; c-Jun, transcription factor AP-1; cGMP, cyclic guanosine monophosphate; PKG, protein kinase G; Rhoa, Ras homolog family member A; Ncx1, codium/calcium exchanger 1; Serca, Sarco/endoplasmic reticulum Ca\(^{2+}\)-ATPase; Dyrk1a, dual specificity tyrosine-(Y)-phosphorylation regulated kinase 1A; CaMK-II\(\gamma\), calcium/calmodulin-dependent protein kinase II \(\gamma\); Nfat, nuclear factor of activated T-cells; GATA6, GATA binding protein 6; GATA4, GATA binding protein 6.

Table 1 summarizes miRNAs that have been implicated in cardiac hypertrophy and their target genes, as well as the experimental platforms and methods used in each study.
**Table 1. Summary of reported miRNAs and their targets in cardiac hypertrophy.**

| miRNAs | Targets | miRNA–mRNA Interaction | Platforms | Remarks | References |
|---------|---------|------------------------|-----------|---------|------------|
|         | mRNA | Signaling Pathway | Luciferase Assay | Gain/Loss of Function | |
| **Anti-hypertrophic** | | | | | |
| miR-1 | Fbln2 | ECM | + | + | AAB rat | 11 |
| | Twf1 | ECM | + | + | NRCMs | 10 |
| | Igf1 | PI3K-Akt | + | + | TAC mouse and AAC rat | 43,44 |
| | Fabp3 | PPAR | + | + | NRCMs and TAC mouse | 45 |
| miR-101 | Rab1a | MAPKK | + | + | TAAC rat | 12 |
| miR-133 | RhoA | cGMP-PKG | + | + | NRCMs and TAC mouse NRCMs and TAC mouse | 13 |
| | Cdc42 | MAPK | + | + | NRCMs and TAC mouse NRCMs and TAC mouse |
| | Nelfa/Whsc2 | Transcription | + | + | NRCMs and TAC mouse NRCMs and TAC mouse |
| miR-145 | GATA6 | cGMP-PKG | + | + | NRCMs and TAC mouse | 14 |
| miR-150 | p300 | FoxO | + | + | NRCMs | 15 |
| miR-185 | Camk2d | Calcium | + | + | NRVMs and TAC mouse NRVMs and TAC mouse | 16 |
| | Ncx1 | cGMP-PKG | + | + | NRVMs and TAC mouse NRVMs and TAC mouse |
| | Nfatc3 | cGMP-PKG | + | + | NRVMs and TAC mouse NRVMs and TAC mouse |
| miR-223 | Tni3k | + | + | NRCMs and TAC mouse | 46 |
| miR-236 | GATA4 | cGMP-PKG | + | + | NRCMs and TAC mouse | 18 |
| miR-30-3p | Xbp1 | VEGF | + | + | H9c2 cells and AAC rat | 40 |
| miR-34a | Atg9a | Autophagy | + | – | NRCMs and TAAC rat | 19 |
| miR-378 | Mapk1 | MAPK | + | + | NRCMs and TAC mouse NRCMs and TAC mouse | 20 |
| | Igf1r | MAPK | + | + | NRCMs and TAC mouse NRCMs and TAC mouse |
| | Grb2 | MAPK | + | + | NRCMs and TAC mouse NRCMs and TAC mouse |
| | Ker1 | MAPK | + | + | NRCMs and TAC mouse NRCMs and TAC mouse |
| miR-9 | Myocardin | cGMP-PKG | + | – | NRCMs | 21 |
| miR-98 | Cyclin D2 | PI3K-AKT | + | – | NRCMs | 22 |
| **Pro-hypertrophic** | | | | | |
| miR-155 | Tp53inp1 | p53 | + | + | NMCFs and AMI mouse | 23 |
| miR-199a | Gok3β | PI3K-AKT | + | + | NRCMs and TG mouse | 25 |
| miR-199b | Dyrk1a | calcineurin/NFAT | + | + | NRCMs and TAC mouse | 27 |
| | Atrogin1 | calcineurin/NFAT | + | + | NRCMs and TAC mouse NRCMs and TAC mouse | 24 |
| | Murf1 | PKC | + | + | NRCMs and TAC mouse NRCMs and TAC mouse |
| miR-208a | Thrap1 | Thyroid hormone | + | + | NRCMs, TAC and TG mouse NRCMs, TAC and TG mouse | 28 |
| | Myostatin | Cell growth/Differentiation | + | + | NRCMs, TAC and TG mouse NRCMs, TAC and TG mouse |
### Table 1. Cont.

| miRNAs | Targets | miRNA–mRNA Interaction | Platforms | Remarks | References |
|--------|---------|------------------------|-----------|---------|------------|
|        | mRNA | Signaling Pathway | Luciferase Assay | Gain/Loss of Function |          |
|        |        |                       |            | Human |           |
|        |        |           |               |  glomerular mesangial cells | [47] |
| miR-21 | Pten | PI3K-AKT | + | – | Human glomerular mesangial cells |
| miR-21-3p | Hdac8 | AKT/GSK3β | + | + | TAC mouse |
| miR-212/132 family | Foxo3 | PI3K-Akt | + | + | H9c2 cells and TAC mouse |
| miR-22 | Sirt1 | AMPK | + | + | NRCMs, miR-22 |
| miR-22 | Hdac4 | AMPK | + | + | NRCMs, miR-22 |
| miR-22 | Pten | PI3K-AKT | + | + | NRCMs |
| miR-221 | p27 | PI3K-AKT | + | + | NRCM, TAC mouse |
| miR-23a | Foxo3a | PI3K-AKT | + | – | NMCms, TAC and TG mouse |
| miR-23a | Lpa1 | PI3K-AKT | + | + | NRCMs |
| miR-27b | Ppary | PPAR | + | + | NRCMs, TAC and TG mouse |
| miR-30a | Beclin 1 | Autophagy | + | + | NRCMs, TAC and TG mouse |
| miR-328 | Serca2a | cGMP-PKG | + | + | NRCMs, TAC and TG mouse |
| miR-350 | Mapk11/14 | MAPK | + | + | H9c2 cells and TAC rats |
| miR-350 | Mapk8/9 | MAPK | + | + | H9c2 cells and TAC rats |

**Abbreviations for mRNAs:** Fbln2, Fibulin 2; Twif1, Twinfilin 1; Igfl1, Insulin-like growth factor 1; Fabp3, Fatty Acid Binding Protein 3; Rab1a, Ras-related protein Rab 1a; Rhoa, Ras homolog family member A; Cdc42, Cell Division Cycle 42; Nelfa/Whsce2, Wolf-Hirschhorn syndrome candidate 2 protein; GATA6, GATA binding protein 6; p300, E1A binding protein p300; CamK2d, calcium/calmodulin-dependent protein kinase II delta; Ncx1, sodium/calcium exchanger 1; Nfatc3, Nuclear factor of activated T-cells, cytoplasmic, calcineurin dependent 3; Tnmi3k, Troponin I type 3 interacting kinase; GATA4, GATA binding protein 4; Xbp1, X-box binding protein 1; Atg9a, autophagy-related 9A; Mapk1, mitogen-activated protein kinase 1; Igf1r, insulin-like growth factor 1 receptor; Grb2, Growth factor receptor bound protein 2; Casr, kinase suppressor of ras 1; Tp53inp1, tumor protein p53 inducible nuclear protein 1; Gsk3β, glycogen synthase kinase 3 β; Dyrk1a, Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a; Murf1, tripartite motif-containing 63; Thrap1, Mediator complex subunit 13; Pten, phosphatase and tensin homolog; Hdac8, histone deacetylase 8; Foxo3, Forkhead box O3; Lpa1, Lysophosphatidic acid receptor 1; Pparγ, peroxisome proliferator-activated receptor γ; Serca2a, Sarco/endoplasmic reticulum Ca²⁺-ATPase 2a; Mapk11/14, mitogen-activated protein kinase 11/14; Mapk8/9, Mitogen-activated protein kinase 8/9. Abbreviations for pathway: ECM, extracellular matrix deposition; PI3K-Akt, phosphatidylinositol 3 kinase-protein kinase B; PPAR, peroxisome proliferator-activated receptor; cGMP-PKG, cyclic guanosine monophosphate-dependent protein kinase G; VEGF, vascular endothelial growth factor; Akt-Gsk3β, protein kinase B-Glycogen synthase kinase 3 β; FoxO, Forkhead box; MAPK, mitogen-activated protein kinase; p53, tumor protein p53; NAFAT, nuclear factor of activated T-cells; PKC, protein kinase C; AMPK, AMP-activated protein kinase. Abbreviations for platforms: AAB rat, abdominal aortic banding rat; NRCMs, neonatal rat cardiomyocytes; TAC mouse, transverse aortic constriction mouse; ACC mouse, abdominal aortic constriction mouse; NMCms, neonatal mouse cardiomyocytes; TAAC rat, transverse abdominal aortic constriction; NRVMs, neonatal rat ventricular myocytes; H9c2 cells, rat myoblast cells; NMCFs, Neonatal mouse cardiac fibroblasts; AMI mouse, acute myocardial infarction mouse; TG mouse, transgenic mouse; KO mouse, knockout mouse; NVRMs, neonatal rat ventricular cells. +/− indicates with or without experimental results to support the regulatory effect of microRNAs on target gene expressions respectively.

### 3. miRNAs in Cardiac Fibrosis

Cardiac fibrosis is a common phenotype, found in several cardiac diseases including myocardial infarction and heart failure, characterized by the adverse accumulation of collagens and other extracellular matrix (ECM) proteins. Early work from Thum et al. [48] demonstrated that miR-21 promotes cardiac fibrosis by targeting extracellular regulated kinase inhibitor sprouty homolog 1
(Spry1) with stimulation of MAPK signaling in cardiac fibroblasts. In a model of myocardial ischemia-reperfusion, miR-21 was found to target Pten and subsequently leading to an increase in matrix metalloprotease 2 (Mmp2). In line with this finding, antagonism of miR-21 results in an increase of Pten in cardiac fibroblasts [49]. In a pioneer study by Olson’s group, expression of miR-29 family members (miR-29a, miR-29b and miR-29c) negatively correlated with expression of genes involved in ECM production and fibrosis after experimental myocardial infarction. Furthermore, the miR-29 family regulates the expression of pro-fibrotic genes, including extracellular matrix genes elastin [50], fibrillin 1 (Fbn1), collagen type I, α 1 and 2 (Col1α1, Col1α2) and collagen type III, α 1 (Col3α1) [51]. In addition, miR-29b targeting Tgfβ1 to play a role in transforming growth factor β (TGFβ)/SMAD3 signaling [52]. Several other miRNAs have been identified as also targeting collagens and TGFβ signaling to play a role in fibrogenesis. For instance, Let-7i and miR-26a attenuate collagen deposition and exert their function through targeting Col1α2 and Col1α1, respectively [23,53,54]. The role of miR-133a in myocardial fibrosis and electrical repolarization in pressure-overloaded adult hearts may reflect its regulatory effects on the expression of Col1α1, Serca2a and calcineurin [55,56]. Recently, miR-101and miR-101a were found to negatively regulate TGFβ signaling through targeting of Tgf receptor type 1 (Tgfβr1) and c-Fos. Cardiac fibrosis is significantly suppressed by upregulation of miR-101a in the rat myocardial infarction model [57,58]. miR-125b is pro-fibrotic via targeting of apelin, one of the key fibrogenesis repressors in the heart [59]. Wang et al. [60] showed that miR-24 could interfere with TGFβ signaling by targeting the pro-protein convertase, furin, and subsequently downregulate the level of TGFβ in cardiac fibroblasts. By targeting connective tissue growth factor (Ctgf), miR-133 and miR-30 are suggested to be important for collagen synthesis [61].

Figure 2 provides a schematic representation of the involvement of known miRNAs in classical fibrogenesis signaling pathways.

**Figure 2.** MiRNAs in cardiac fibrosis pathway. MiRNAs regulate cardiac fibrosis process by targeting the key molecules that mediate transcription of ECM genes and TGFβ signaling. MiRNAs colored in blue indicate anti-fibrosis function, miRNAs colored in purple indicate pro-fibrosis function. Dashed lines indicate translocation of molecules from cytoplasm to nucleus. Ctgf, connective tissue growth factor; Rho-GTP, Rho-GTPase-activating protein; ROCK, Rho associated coiled-coil containing protein kinase; SRF, Serum response factor; Col1α1, Collagen, type 1 α 1; COL1α2, collagen, type 1 α 2; COL3α1, collagen, type 3 α 1; Tgfβ1, transforming growth factor β 1; TgfβR1, transforming growth factor β receptor 1; Smad2/3, SMAD family member 2/3; Snail1, snail family zinc finger 1; IL6, Interleukin 6; IL6R, interleukin 6 receptor; JAK1, Janus kinase 1; STAT3, signal transducer and activator of transcription 3; c-Fos, FBJ murine osteosarcoma viral oncogene homolog; Spry1, sprouty homolog 1. Dash line arrows indicate the relocation of proteins; solid lines arrows indicate signaling cascades.
Table 2 lists miRNAs related to cardiac fibrogenesis, their target genes, and the experimental platforms used in studies.

| miRNAs | Targets | miRNA–mRNA Interaction | Platforms | Remarks | References |
|--------|---------|------------------------|-----------|---------|------------|
|        | mRNA Signaling Pathway | Luciferase Assay | Gain/Loss of Function |          |            |
|        |                     |                       |           |         |            |
| **Anti-fibrosis** | | | | | |
| Let-7i | IL6 | PI3K-AKT | + | + | NRCMs, NRCFs and Ang II induced mouse | [54] |
|        | Col1α2 | ECM | + | + | NRCMs, NRCFs and Ang II induced mouse | |
| miR-101a | c-Fos | MAPK | + | + | NRCFs and MI rat | [57] |
|        | Tgfβ1 | TGFβ | + | + | NRCFs and MI rat | [58] |
| miR-133, miR-30 | Ctgf | TGFβ | + | + | RCMs, RCFs and Ren2 rat | [61] |
| miR-133a | Sna1 | EMT | + | + | MEFs | [62] |
|        | Collα1 | ECM | + | – | Ang II induced rat | [56] |
| miR-24 | Furin | TGFβ | – | + | MCFs and MI mouse | [60] |
| miR-26a | Collα1 | PI3K-AKT | + | + | NRCFs, TAC and miR-26a TG mouse | [53] |
|        | Ctgf | ECM | + | + | NRCFs, TAC and miR-26a TG mouse | |
| miR-29 | Eln | Protein digestion/absorption | + | – | RCFs and MI mouse | |
|        | Fbn1 | ERK | + | – | RCFs and MI mouse | [51] |
|        | Collα1 | ECM | + | + | RCFs and MI mouse | |
|        | Collα2 | ECM | + | + | RCFs and MI mouse | |
|        | Collα3 | ECM | + | + | RCFs and MI mouse | |
| miR-29b | Tgfβ1 | TGFβ | – | + | MCFs | [52] |
| **Pro-fibrosis** | | | | | |
| miR-125b | Apelin | TGFβ | + | + | HCFs, TAC and Ang II induced mouse | [59] |
| miR-21 | Spry1 | ERK-MAPK | + | + | NRCFs, NRCMs, TAC and TG mouse | [48] |
|        | Pten | PI3K-AKT | + | + | MCF and IR mouse | [49] |

Abbreviations for mRNAs: IL6, Interleukin 6; Collα1, Collagen, type I, α 2; c-Fos, FBJ murine osteosarcoma viral oncogene homolog; Tgfβ1, Transforming growth factor β receptor 1; Ctgf, connective tissue growth factor; sna1, snail family zinc finger 1; Collα1, collagen, type I α 1; Eln, Elastin; Fbn1, Fibrillin 1; Collα3, collagen, type I, α 3; Tgfβ1, transforming growth factor β 1; Spry1, sprouty homolog 1; Pten, Phosphatase and tensin homolog. Abbreviations for pathway: PI3K-AKT, phosphatidylinositol 3 kinase–protein kinase B; MAPK, mitogen-activated protein kinase; TGF-β, transforming growth factor β; ERK, extracellular signal-regulated kinases; ECM, extracellular matrix. Abbreviations for platforms: NRCMs, neonatal rat cardiomyocytes; NRCFs, neonatal rat cardiac fibroblasts; Ang II, angiotensin II; MI, myocardial infarction; RCMs, rat cardiac fibroblasts; RCFs, rat ventricular myocytes; MCFs, mouse embryonic fibroblasts; MCFs, mouse cardiac fibroblasts; HCFs, normal human cardiac fibroblasts; TG mouse, transgenic mouse; TAC, transverse aortic constriction mouse. +/– indicates with or without experimental results to support the regulatory effect of microRNAs on target gene expressions respectively.

4. miRNAs in Cardiomyocyte Apoptosis

Apoptosis is programmed cell death which normally ensures proper functional and metabolic homeostasis in multicellular organisms. As with other eukaryotic cells, apoptosis in cardiomyocytes may be triggered by the activation of two main pathways, an extrinsic pathway that is mediated by death receptors, and an intrinsic pathway that involves mitochondrial permeability/transmembrane potential. Both pathways are known to activate initiator caspases (caspase 8, 9, 10) and finally the apoptosis executioner, caspase 3 (Casp3) [63]. Results from one recent study demonstrated that miR-133 and miR-874 negatively regulate the expression of Casp3 and Casp8, respectively, and protect
cardiomyocytes from cell death induced by oxidative stress [64]. MiR-133 also regulates expression of Casp9 with subsequent reduction in Casp3 levels in nicotine-induced cell death [65]. Casp3 is also targeted by miR-378 with consequent attenuation of ischemia-induced apoptosis [66]. Srivastava and colleagues used an ischemia-reperfusion injury rat model to show the beneficial effect of ischemic post-conditioning may be mediated by the regulatory effect of miR-133a on Casp9 [67]. In addition to caspases, miRNAs have also been shown to target the B-cell lymphoma 2 (Bcl2) family within the intrinsic mitochondrial apoptosis pathway. Functionally, these miRNAs could be divided into anti-apoptosis and pro-apoptosis sub-families. At present, miR-1, miR-15b, miR-30b, miR-34a, and miR-497 are reported to promote cardiomyocyte cell death through repression of Bcl2 (anti-apoptotic) gene expression whereas miR-149 and miR-24 repress apoptosis by targeting the pro-apoptotic genes Puma and Bim [68–74].

In addition to targeting Bcl2 or caspase families, miRNAs were reported to target various components of the upstream apoptosis-related signaling cascades. For instance, miR-1 mediates apoptosis of H9c2 cells induced by high glucose, by suppressing the expression of anti-apoptotic genes such as insulin-like growth factor (Igf1). In a transgenic mouse overexpression of miR-1 exacerbated cardiac apoptosis secondary to ischemia-reperfusion. Further mechanistic studies revealed that protein kinase C ε (Pkcε) and heat shock protein 60 (Hsp60) are targets for miR-1 [75,76]. Similarly, miR-320 promotes apoptosis of cardiomyocytes by reducing the level of heat shock protein 20 (Hsp20) [77].

In contrast to be the positive regulators of cardiac apoptosis, several miRNAs such as miR-21, miR-199a, and miR-30 have been reported to antagonize apoptosis of cardiac cells. Multiple lines of evidence demonstrate that miR-21 attenuates cardiac apoptosis secondary to oxidative stress-induced cardiac apoptosis by suppressing expression of programmed cell death 4 (Pdc4) [78,79]. The protective role of miR-21 against cardiac apoptosis is further substantiated by the observation that during hydrogen peroxide-induced injury in cardiac myocytes knockdown of miR-21 induces, while upregulation of miR-21 protects against, cell death [79]. MiR-21 also suppresses apoptosis induced by hypoxia through targeting of the PTEN/AKT pathway [80]. Like miR-21, miR-199a regulates the expression of hypoxia-inducible factor 1 α (Hif1α) and a class II histone deacetylase, sirtuin 1 (Sirt1). Overexpression of miR-199a under hypoxic conditions downregulates Hif1α and Sirt1 with subsequent suppression of p53 and attenuation of hypoxia-induced cardiomyocyte apoptosis [81]. Interestingly, one study demonstrated that p53 is also targeted by the miR-30 family (miR-30a-e). In apoptosis induced by oxidative stress, downregulation of miR-30 upregulates p53 and dynamin-related protein 1 (Drp1), an inhibitor of mitochondrial fission, finally culminating in apoptosis [82]. The miR-30 family was found to mediate doxorubicin-induced apoptosis in adult rat cardiomyocytes. Additional experiments demonstrated that miR-30 targets multiple genes in the β-adrenergic signaling pathway including β1 and β2 adrenoceptors and G protein α i subunit (Gi2) [83]. Several other miRNAs have been demonstrated to play critical roles in hypoxia-induced apoptosis in cardiomyocytes. Among them, miR-100, miR-101, miR-132, miR-15b, miR-20a, and miR-92a were found to enhance apoptosis by targeting negative regulators/factors in the intrinsic apoptosis pathway [69,81,84–88]. In contrast, miR-133a, miR-138, and miR-146b were demonstrated to attenuate hypoxia-induced apoptosis by targeting different upstream signaling pathways [80,89–92]. Numerous other miRNAs have been demonstrated to exert pro-apoptotic or anti-apoptotic effects by targeting various signaling networks upstream of the intrinsic apoptosis pathway.

Figure 3 illustrates the involvement of known miRNAs in classical signaling pathways regulating apoptosis.

Apoptosis is a complex and highly sophisticated series of physiological events that can be divided into three phases, namely initiation, propagation, and execution [93]. Several microRNAs reviewed in this section were found to directly target the key molecules involved in different apoptotic phases. Through their modulating influence on apoptotic signaling pathways, miRNAs can exert pro-apoptotic or anti-apoptotic effects and, thus, can have a profound influence on cardiac cell survival. For instance, miR-132, miR-145, miR-214, and miR-25 were demonstrated to target the intracellular
calcium regulating pathway and subsequently inhibit the initiation of apoptosis \cite{86,94–96}. miR-24 was found to negatively regulate expression of the pro-apoptosis Bcl-2 family protein, Bim, and represses the initiation of mitochondrial and ER stress-induced apoptosis \cite{74}. Conversely, miR-1 and miR-30b were shown to directly suppress the expression of Bcl-2 and facilitate the initiation of apoptotic processes in cardiomyocytes in various disease models \cite{70,76}. miR-133 and miR-17 were reported to regulate the expression of Casp9 and apoptotic protease-activating factor 1 (Apaf-1), respectively, the key molecules in apoptosis propagation \cite{65,97}. MiR-378 was demonstrated to suppress the expression of Casp3 and block the entry to the execution phase in cardiomyocytes \cite{66}. Known cardiac apoptosis-related miRNAs and their target genes, as well as the experimental platforms and methods used in studies are summarized in Table 3.

**Figure 3.** MiRNAs in cardiomyocyte apoptosis pathway. MiRNAs regulate cardiac apoptotic processes by targeting key molecules in mitochondria, endoplasmic reticulum, as well as, JAK-STAT3 and PI3K/AKT pathways. MiRNAs colored in blue indicate the anti-apoptosis functions, miRNAs colored in purple indicate pro-apoptosis functions. β1AR, adrenergic receptor β 1; β2AR, adrenergic receptor β 2; Gαi2, G protein α i subunit; PKG, cGMP-dependent protein kinase; RhoA, Ras homolog family member A; STAT3, Signal transducer and activator of transcription 3; Rock1, Rho associated coiled-coil containing protein kinase 1; SRF, serum response factor; Ncx1, sodium/calcium exchanger 1; Nhe1, Na+ /H+ exchanger 1; Prkcc, protein kinase C ε; Mcu, mitochondrial calcium uniporter; Bcl2, B-cell CLL/lymphoma 2; Bim, Bcl2 like 11; ILs, Interleukins; JAK1, Janus kinase 1; STAT3, signal transducer and activator of transcription 3; c-Fos, FBJ murine osteosarcoma viral oncogene homolog; TNF, tumor necrosis factor; TNFR1, tumor necrosis factor receptor 1; GFs, growth factors; RTK, receptor tyrosine kinases; PI3K, phosphatidylinositol 3 kinase; Pten, phosphatase and tensin homolog; AKT, Protein kinase B; Mlk3, mitogen-activated protein kinase 11; JNK, mitogen-activated protein kinase 8; c-Jun, transcription factor AP-1-like; Gsk3β, glycogen synthase kinase 3 β; CCND1, cyclin D1; MYC, myelocytomatosis oncogene; Foxo3a, Forkhead box O 3a; FasL, Fas ligand; Bnip3, Bcl2/adenovirus E1B 19 kDa interacting protein 3; Casp9, caspase 9; Casp3, caspase 3; m-TOR, mechanistic target of rapamycin; Hif1α, hypoxia-inducible factor 1, α subunit; Phd3, Egl-9 family hypoxia-inducible factor 3; p53, Tumor protein p53; Puma, Bcl2 binding component 3; Apaf1, Apoptotic peptidase activating factor 1; PERK, eukaryotic translation initiation factor 2 α kinase 3; Atf6, activating transcription factor 6; Nrf2, nuclear factor, erythroid 2 like 2; ERSE, ER stress response element; ER, endoplasmic reticulum. Dash line arrows indicate the relocation of proteins; solid line arrows indicate signaling cascades.
Table 3. Summary of reported miRNAs and their targets in cardiac apoptosis.

| miRNAs  | mRNA Signaling Pathway | miRNA–mRNA Interaction | Platforms | Remarks | References |
|---------|------------------------|------------------------|-----------|---------|------------|
|         |                        |                        |           |         |            |
|         |                        |                        |           |         |            |
|         |                        |                        |           |         |            |
|         |                        |                        |           |         |            |
|         |                        |                        |           |         |            |
| miR-132 | Ncx1                   | cGMP-PKG and Calcium   | +         | –       | NRCMs      | [86]       |
| miR-133 | Casp9                  | ERK-MAPK               | +         | –       | NRCMs      | [65]       |
| miR-133a| Tagln2                 | CASP8/CASP3            | +         | –       | H9c2 cells | [89]       |
| miR-138 | Mlik3                  | TNF                    | +         | –       | H9c2 cells | [90]       |
| miR-144 | Nrf2                   | ROS formation          | +         | –       | NRCMs      | [98]       |
| miR-145 | Bnip3                  | FOXO                   | +         | –       | I/R mouse  | [99]       |
| miR-149 | Puma                   | p33                    | +         | –       | NMCMs      | [73]       |
| miR-17  | Apaf1                  | p33                    | +         | –       | NRCMs      | [97]       |
| miR-185 | Nhe1                   | cAMP                   | +         | –       | NRVMs      | [100]      |
| miR-199a| Hft1a                  | mTOR                   | +         | –       | NRCMs      | [81]       |
| miR-20a | Egln3/Phd3             | HIF1                   | +         | +       | NRCMs      | [87]       |
| miR-21  | Pdcd4                  | NfkB                   | +         | +       | NRCMs      | [78]       |
|         | Fasl                   | PI3K-AKT               | +         | +       | NRCMs and miR-21 TG mouse | [101]    |
| miR-214 | Ncx1                   | Calcium                | –         | +       | NRCM and miR-214 KO mouse | [95]     |
| miR-24  | Bim                    | Mitochondrial apoptosis| +         | –       | NMCMs      | [74]       |
| miR-25  | Mccu                   | Mitochondrial Ca\(^{2+}\) homeostasis | +         | +       | H9c2 cells | [96]       |
|         | β1AR                   | β-adrenergic pathway   | +         | +       | Mi rat, DOX-induced HF rat, ARCM and H9c2 cells | [83] |
|         | β2AR                   | β-adrenergic pathway   | +         | +       | Mi rat, DOX-induced HF rat, ARCM and H9c2 cells | [83] |
| miR-30  | Bnip3L/Nix             | mitochondrial apoptosis| +         | +       | Mi rat, DOX-induced HF rat, ARCM and H9c2 cells | [83] |
|         | Gqβ2                   | β-adrenergic pathway   | +         | +       | Mi rat, DOX-induced HF rat, ARCM and H9c2 cells | [83] |
|         | p53                   | p33                    | +         | +       | NRCMs      | [82]       |
| miR-378 | Casp3                  | MAPK                   | +         | +       | H9c2 cells and AMI rat | [66] |
| miR-494 | Pten                   | PI3K-AKT               | +         | +       | miR-494 TG Mouse | [102] |
|         | Rock1                  | cGMP-PKG               | +         | +       | miR-494 TG Mouse | [102] |
|         | CamkIIδ                | HIF1                   | +         | +       | miR-494 TG Mouse | [102] |
|         | Fgfr2                  | PI3K-AKT               | +         | +       | miR-494 TG Mouse | [102] |
|         | Lif                    | TNF                    | +         | +       | miR-494 TG Mouse | [102] |
| miR-499 | Pdcd4                  | Mitochondrial apoptosis| +         | +       | NRCMs      | [103] |
| miR-702 | Atf6                   | Protein process in ER  | +         | –       | ISO treated mouse and NIH3T3 cells | [105] |
| miR-761 | Mff                    | Mitochondrial apoptosis| +         | –       | NRCMs      | [106] |
| miR-7a/b| Parp                   | DNA repair & cytoskeletal organization | +         | +       | H9C2 cells and I/R rat | [107] |
Table 3. Cont.

| miRNAs | Targets | miRNA–mRNA Interaction | Platforms | Remarks | References |
|--------|---------|------------------------|-----------|---------|------------|
|        |          |                        |           |         |            |
| **Pro-apoptotic** | | | | | |
| miR-1  | Prkce   | cGMP-PKG               | +         | +       | LNA-antimiR-1 treated mouse | [76] |
|        | Hsp60   | RNA degradation         | +         | +       | LNA-antimiR-1 treated mouse | [68] |
|        | Bcl2    | Mitochondrial          | +         | +       | H9c2 cells and I/R rat    | [69] |
| miR-140| Mfn1     | Mitochondrial          | +         | +       | NRCMs      | [108] |
| miR-146b| RNase L | NFkB                   | +         | –       | H9c2 cells | [91] |
| miR-15b| Bcl2    | Mitochondrial          | –         | +       | NRVCs and I/R rat  | [109] |
| miR-17-5p| Stat3  | Jak-STAT               | +         | +       | NRVCs and I/R rat  | [110] |
| miR-181a| Gpx1     | Mitochondrial          | +         | +       | H9c2 cells | [111] |
| miR-195| Sirt1   | AMPK                   | +         | +       | NMCMs      | [112] |
| miR-210| Aitm3   | AKT/p53                | +         | +       | H9c2 cells and NRCMs | [113] |
| miR-26a| Gsk3β   | PI3K-AKT               | +         | +       | NRCMs      | [114] |
| miR-30b| Bcl2    | Mitochondrial          | +         | +       | NRCMs      | [115] |
| miR-30d| Foxo3α  | PI3K-AKT               | +         | +       | STZ-induced diabetic rat, NRCMs | [116] |
| miR-34a| Aldh2   | Oxidative stress       | +         | +       | NRVCs and MI rat | [72] |
| miR-497| Bcl2    | Mitochondrial          | –         | +       | NRCMs, MI, IR mouse | [117] |
| miR-539| Phb2    | Mitochondrial          | +         | +       | NMCMs and I/R mouse | [118] |
| miR-92a| Smad7   | TGFβ                   | +         | +       | H9c2 cells | [88] |

Abbreviations for mRNAs: Ncx1, sodium/calcium exchanger 1; Casp9, caspase 9; Tagln2, Transgelin 2; Mlk3, mixed-lineage protein kinase 3; Nrf2, Nuclear factor, erythroid 2 like 2; Binp3, BCL2/adenoavirous E1B 19kDa interacting protein 3; CamkIIδ, calcium/calmodulin-dependent protein kinase II, δ; Puma, BCL2 binding component 3; Apaf1, apoptotic peptidase activating factor 1; Nhe1, Na+/H+ exchanger 1; Hifα/β, hypoxia-inducible factor α, β subunits; Sirt1, Sirtuin 1; Egln3/PHD3, Egl-9 family hypoxia-inducible factor 3; Pdcd4, programmed cell death 4; Fasl, Fas ligand, Bim, BCL2-like protein 11; Muc, mitochondrial calcium uniporter; β1AR, adrenoceptor β 1; β2AR, adrenoceptor β 2; Nip3L/Nix, BCL2/adenoavirous E1B interacting protein 3-like; Gαi2, G protein α i subunit; Casp3, caspase 3; Pien, Phosphatase and tensin homolog; Rock1, Rho-associated coiled-coil containing protein kinase 1; Fgfr2, Fibroblast growth factor receptor 2; Lif, leukemia inhibitory factor; Pacs2, phosphomofin acidic cluster sorting protein 2; Dyrk2, dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2; Sox6, sex-determining region Y box 6; Atf6, activating transcription factor 6; Ifi30, mitochondrial fission factor; Parp, poly-(ADP-ribose) polymerase; Pkcε, protein kinase C epsilon; Hsp60, Heat shock protein 60; Bcl2, B-cell CLL/lymphoma 2; Mfn1, Mitofusin 1; RNase L, ribonuclease L; Stat3, signal transducer and activator of transcription 3; Gpx1, glutathione peroxidase 1; Gsk3β, glycogen synthase kinase 3-β; Aif, apoptosis inducing factor, mitochondria associated 3; Foxo3α, Forkhead box O3A; TGFβ, transforming growth factor β. Abbreviations for platforms: NRCMs, neonatal rat cardiomyocytes; H9c2 cells, rat myoblast cells; I/R, Ischemia/reperfusion; NRVCs, neonatal rat ventricular cells; STZ, Streptozotocin; MI rat, myocardial infarction rat. +/– indicates with or without experimental results to support the regulatory effect of microRNAs on target gene expressions respectively.
5. Future Perspectives

MiRNAs have emerged as vital post-transcriptional regulators involved in almost all biological processes ranging from development, such as stem cell differentiation, to maintenance of cell and tissue integrity for multiple physiological functions. The roles of miRNAs in cardiovascular pathophysiological events and the therapeutic potential of targeting specific miRNA in ameliorating progression towards cardiac hypertrophy, fibrosis, and apoptosis are under ongoing exploration in various in vitro and in vivo disease models. Clearly, as discussed in this review, each cardiac pathophysiological event is regulated by multiple microRNAs. As illustrated in Table 4, a number of known microRNAs are not functionally restricted but have been shown to participate in multiple aspects of cardiac pathophysiology. Since the predominant cardiovascular diseases such as heart failure or hypertension result from complex pathophysiology the elucidation of the roles of multifunctional disease-related miRNAs will provide targets for developing therapeutics able to simultaneously suppress multiple disease-mediating pathological pathways. Recent technological advances in unraveling the complexity of miRNA biology and function, particularly in relation to the cardiovascular system, is crucial for accurate translation of knowledge to alter specific disease-causing signaling cascades, making the development of miRNA-mediated clinical intervention a reachable reality in the near future. However, the challenge remains particularly in integrating laboratory and clinical findings to design innovative research platforms to translate research findings into clinical applications such as biomarkers and/or therapeutic intervention.

Table 4. Summary of multi-functional miRNAs in cardiovascular pathophysiology.

| miRNAs  | Cardiac Hypertrophy | Cardiac Fibrosis | Cardiomyocyte Apoptosis |
|---------|---------------------|------------------|-------------------------|
| miR-1   | √                   |                  | √                       |
| miR-101 | √                   | √                |                         |
| miR-133 | √                   | √                | √                       |
| miR-145 | √                   | √                |                         |
| miR-199a| √                   |                  |                         |
| miR-21  | √                   |                  | √                       |
| miR-24  | √                   |                  | √                       |
| miR-30  | √                   |                  | √                       |
| miR-34a | √                   |                  |                         |
| miR-378 | √                   |                  | √                       |

√ indicates the involvement of microRNA in different cardiovascular pathological events.

Cardiovascular diseases, such as heart failure (HF), are complex with contributions from various genomic, genetic, and environmental factors. To date, although numerous genome-wide studies have revealed differential expression patterns of miRNAs in HF compared to controls, signature miRNA profiles for HF have yet to be definitively identified. By compiling reports from different HF cohorts it is apparent a number of apoptosis-related miRNAs display consistent differential expression patterns in various biological specimens including serum, plasma and cardiac tissue. For instance, miR-1 and miR-21 were originally demonstrated to play roles in cardiac remodeling and apoptosis-related signaling in cellular and animal models. A later genome-wide miRNA study revealed that these two miRNAs together with several other cardiac hypertrophy-related miRNA (miR-23) and apoptosis-related miRNAs (miR-195 and miR-199), were differentially expressed in myocardial biopsies from HF patients compared with controls, suggesting the pervasive involvement of these miRNAs in the pathology of HF [117]. Similarly, another cluster of apoptosis-related miRNAs (miR-145, miR-214, miR-378, and miR-7), as well as miR-1 were found differentially expressed in HF cardiac tissues in another study [118]. One recent HF cohort study revealed differential expression of a cluster of hypertrophy-related miRNAs (miR-101 and miR-22), a cluster of apoptosis-related miRNAs (miR-17, miR-30a, and miR-92a) and miR-21 in serum [119]. Further comparisons of 10 selected miRNAs listed in Table 4 with data originating from 9 HF cohorts [117–124] revealed...
that most of these multifunctional miRNAs are reported as dysregulated in more than one cohort study, suggesting clinical significance. Amongst these, miR-1 was shown to be differentially expressed in four cohorts [117,118,122,124], and miR-21 was reported to differentially expressed in two cohort studies [117,119]. Comparative evaluation across different data bases, particularly in multiple sample types, investigative models, patient cohorts and disease phenotypes, is necessary to shortlist candidate miRNAs for development of putative therapeutic applications in the future.

Over the past decade the essential roles of miRNAs in the biology and cellular dysfunction of cardiovascular pathologies have been revealed at an increasing pace. In this article, by compiling miRNAs associated with cardiac hypertrophy, fibrosis, and apoptosis, we hope to bring insights for the roles of miRNAs in cardiac remodeling pathways to the readers. This body of information provides the foundation for further innovative research towards development of miRNA-based diagnostic methods and therapeutics.

Acknowledgments: This work is supported by National University of Singapore-Cardiovascular Research Institute (NUS-CVRI) core fund, N-172-000-047-001.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509–524. [CrossRef] [PubMed]
2. Zhao, Y.; Ransom, J.F.; Li, A.; Vedantham, V.; von Drehle, M.; Muth, A.N.; Tsuhihashi, T.; McManus, M.T.; Schwartz, R.J.; Srivastava, D. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007, 129, 303–317. [CrossRef] [PubMed]
3. Saxena, A.; Tabin, C.J. miRNA-processing enzyme Dicer is necessary for cardiac outflow tract alignment and chamber septation. Proc. Natl. Acad. Sci. USA 2010, 107, 87–91. [CrossRef] [PubMed]
4. Da Costa Martins, P.A.; Bourajjaj, M.; Gladka, M.; Kortland, M.; van Oort, R.J.; Pinto, Y.M.; Molkentin, J.D.; de Windt, L.J. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008, 118, 1567–1576. [CrossRef] [PubMed]
5. Greenland, P.; Alpert, J.S.; Beller, G.A.; Benjamin, E.J.; Budoff, M.J.; Fayad, Z.A.; Foster, E.; Hlatky, M.A.; Hodgson, J.M.; Kushner, F.G.; et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010, 122, e584–e636. [CrossRef] [PubMed]
6. Thum, T.; Mayr, M. Review focus on the role of microRNA in cardiovascular biology and disease. Cardiovasc. Res. 2012, 93, 543–544. [CrossRef] [PubMed]
7. Condorelli, G.; Latronico, M.V.; Cavarretta, E. microRNAs in cardiovascular diseases: Current knowledge and the road ahead. J. Am. Coll. Cardiol. 2014, 63, 2177–2187. [CrossRef] [PubMed]
8. Bronze-da-Rocha, E. MicroRNAs expression profiles in cardiovascular diseases: Current knowledge and the road ahead. J. Am. Coll. Cardiol. 2014, 63, 2177–2187. [CrossRef] [PubMed]
9. Sayed, D.; Hong, C.; Chen, I.Y.; Lypowy, J.; Abdellatif, M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ. Res. 2007, 100, 416–424. [CrossRef] [PubMed]
10. Li, Q.; Song, X.W.; Zou, J.; Wang, G.K.; Kremneva, E.; Li, X.Q.; Zhu, N.; Sun, T.; Lappalainen, P.; Yuan, W.J.; et al. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J. Cell Sci. 2010, 123 Pt 14, 2444–2452. [CrossRef] [PubMed]
11. Karakikes, I.; Chaanine, A.H.; Kang, S.; Mukete, B.N.; Jeong, D.; Zhang, S.; Hajjar, R.J.; Lebeche, D. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J. Am. Heart Assoc. 2013, 2, e00078. [CrossRef] [PubMed]
12. Wei, L.; Yuan, M.; Zhou, R.; Bai, Q.; Zhang, W.; Zhang, M.; Huang, Y.; Shi, L. MicroRNA-101 inhibits rat cardiac hypertrophy by targeting Rab1a. J. Cardiovasc. Pharmacol. 2015, 65, 357–363. [CrossRef] [PubMed]
13. Care, A.; Catalucci, D.; Felicetti, F.; Bonci, D.; Addario, A.; Gallo, P.; Bang, M.L.; Segalini, P.; Gu, Y.; Dalton, N.D.; et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 2007, 13, 613–618. [CrossRef] [PubMed]
14. Li, R.; Yan, G.; Zhang, Q.; Jiang, Y.; Sun, H.; Hu, Y.; Sun, J.; Xu. miR-145 inhibits isoproterenol-induced cardiomyocyte hypertrophy by targeting the expression and localization of GATA6. *FEBS Lett.* **2013**, *587*, 1754–1761. [CrossRef] [PubMed]

15. Duan, Y.; Zhou, B.; Su, H.; Liu, Y.; Du. miR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300. *Exp. Cell Res.* **2013**, *319*, 173–184. [CrossRef] [PubMed]

16. Kim, J.O.; Song, D.W.; Kwon, E.J.; Hong, S.E.; Song, H.K.; Min, C.K.; Kim. D.H. miR-185 plays an anti-hypertrophic role in the heart via multiple targets in the calcium-signaling pathways. *PLoS ONE* **2015**, *10*, e0122509. [CrossRef] [PubMed]

17. Wang, C.; Wang, S.; Zhao, P.; Wang, X.; Wang, J.; Wang, Y.; Song, L.; Zou, Y.; Hui, R. MiR-221 promotes cardiac hypertrophy *in vitro* through the modulation of p27 expression. *J. Cell. Biochem.* **2012**, *113*, 2040–2046. [CrossRef] [PubMed]

18. Han, M.; Yang, Z.; Sayed, D.; He, M.; Gao, S.; Lin, L.; Yoon, S.; Abdellatif, M. GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy. *Cardiovasc. Res.* **2013**, *93*, 645–654. [CrossRef] [PubMed]

19. Huang, J.; Sun, W.; Huang, H.; Ye, J.; Pan, W.; Zhong, Y.; Cheng, X.; You, X.; Liu, B.; Xiong, L.; et al. miR-34a modulates angiotensin II-induced myocardial hypertrophy by direct inhibition of ATG9A expression and autophagic activity. *PLoS ONE* **2014**, *9*, e94382. [CrossRef] [PubMed]

20. Ganesan, J.; Ramanujam, D.; Sassi, Y.; Ahles, A.; Jentzsch, C.; Werfel, S.; Leierseder, S.; Loyer, X.; Giacca, M.; Zentilin, L.; et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. *Circulation* **2013**, *127*, 2097–2106. [CrossRef] [PubMed]

21. Wang, K.; Long, B.; Zhou, J.; Li. P.F. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. *J. Biol. Chem.* **2010**, *285*, 11903–11912. [CrossRef] [PubMed]

22. Yang, Y.; Ago, T.; Zhai, P.; Abdellatif, M.; Sadoshima, J. Thioredoxin 1 negatively regulates angiotensin II-induced cardiac hypertrophy through upregulation of miR-98/let-7. *Circ. Res.* **2011**, *108*, 305–313. [CrossRef] [PubMed]

23. He, W.; Huang, H.; Xie, Q.; Wang, Z.; Fan, Y.; Kong, B.; Huang, D.; Xiao, Y. MiR-155 knockout in fibroblasts improves cardiac remodeling by targeting tumor protein p53-inducible nuclear protein 1. *J. Cardiovasc. Pharmacol. Ther.* **2015**, in press. [CrossRef] [PubMed]

24. Song, D.W.; Ryu, J.Y.; Kim, J.O.; Kwon, E.J.; Kim do, H. The miR-19a/b family positively regulates cardiomyocyte hypertrophy by targeting atrogin-1 and MuRF-1. *Biochem. J.* **2014**, *457*, 151–162. [CrossRef] [PubMed]

25. Li, Z.; Song, Y.; Liu, L.; Hou, N.; An, X.; Zhan, D.; Li, Y.; Zhou, L.; Li, P.; Yu, L.; et al. miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation. *Cell Death Differ.* **2015**, in press. [CrossRef] [PubMed]

26. Rane, S.; He, M.; Sayed, D.; Yan, L.; Vatner, D.; Abdellatif, M. An antagonism between the AKT and β-adrenergic signaling pathways mediated through their reciprocal effects on miR-19a-5p. *Cell Signal.* **2010**, *22*, 1054–1062. [CrossRef] [PubMed]

27. Da Costa Martins, P.A.; Salic, K.; Gladka, M.M.; Armand, A.S.; Leptidis, S.; el Azzouzi, H.; Hansen, A.; Coenen-de Roo, C.J.; Bierhuizen, M.F.; van der Nagel, R.; et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. *Nat. Cell Biol.* **2010**, *12*, 1220–1227. [CrossRef] [PubMed]

28. Callis, T.E.; Pandya, K.; Sek, H.Y.; Tang, R.H.; Tatsuguchi, M.; Huang, Z.P.; Chen, J.F.; Deng, Z.; Gunn, B.; Shumate, J.; et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. *J. Clin. Investig.* **2009**, *119*, 2772–2786. [CrossRef] [PubMed]

29. Adam, O.; Lohfelm, B.; Thum, T.; Gupta, S.K.; Puhl, S.L.; Schafer, H.J.; Bohm, M.; Laufs, U. Role of miR-21 in the pathogenesis of atrial fibrosis. *Basic Res. Cardiol.* **2012**, *107*, 278. [CrossRef] [PubMed]

30. Yan, M.; Chen, C.; Gong, W.; Yin, Z.; Zhou, L.; Chaugai, S.; Wang, D.W. miR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8. *Cardiovasc. Res.* **2015**, *105*, 340–352. [CrossRef] [PubMed]

31. Bang, C.; Batkai, S.; Dangwal, S.; Gupta, S.K.; Foinquinos, A.; Holzmann, A.; Just, A.; Remke, J.; Zimmer, K.; Zeug, A.; et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. *J. Clin. Investig.* **2014**, *124*, 2136–2146. [PubMed]
32. Ucar, A.; Gupta, S.K.; Fiedler, J.; Erikeri, E.; Kardasinski, M.; Batkai, S.; Dangwal, S.; Kumarswamy, R.; Bang, C.; Holzmann, A.; et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun. 2012, 3, 1078. [CrossRef] [PubMed]

33. Wang, K.; Lin, Z.Q.; Long, B.; Li, J.H.; Zhou, J.; Li, P.F. Cardiac hypertrophy is positively regulated by MicroRNA miR-23a. J. Biol. Chem. 2012, 287, 589–599. [CrossRef] [PubMed]

34. Yang, J.; Nie, Y.; Wang, F.; Hou, J.; Cong, X.; Hu, S.; Chen, X. Reciprocal regulation of microRNAs-23a and lysophosphatidic acid receptor signaling in cardiomyocyte hypertrophy. Biochim. Biophys. Acta 2013, 1831, 1386–1394. [CrossRef] [PubMed]

35. Xu, X.D.; Song, X.W.; Li, Q.; Wang, G.K.; Jing, Q.; Qin, Y.W. Attenuation of microRNA-22 derepressed PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. Cell. Physiol. Biochem. 2013, 31, 997–1008. [CrossRef] [PubMed]

36. Huang, Z.P.; Chen, J.; Seok, H.Y.; Zhang, Z.; Kataoka, M.; Hu, X.; Wang, D.Z. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ. Res. 2013, 112, 1234–1243. [CrossRef] [PubMed]

37. Tu, Y.; Wan, L.; Bu, L.; Zhao, D.; Dong, D.; Huang, T.; Cheng, Z.; Shen, B. MicroRNA-22 downregulation by atorvastatin in a mouse model of cardiac hypertrophy: A new mechanism for antihypertrophic intervention. Cell. Physiol. Biochem. 2013, 31, 997–1008. [CrossRef] [PubMed]

38. Wang, J.; Song, Y.; Zhang, Y.; Xiao, H.; Sun, Q.; Hou, N.; Guo, S.; Wang, Y.; Fan, K.; Zhan, D.; et al. Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Res. 2012, 22, 516–527. [CrossRef] [PubMed]

39. Pan, W.; Zhong, Y.; Cheng, C.; Liu, B.; Wang, L.; Li, A.; Xiong, L.; Liu, S. miR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy. PLoS ONE 2013, 8, e53950. [CrossRef] [PubMed]

40. Duan, Q.; Chen, C.; Yang, L.; Li, N.; Gong, W.; Li, S.; Wang, D.W. MicroRNA regulation of unfolded protein response transcription factor XPB1 in the progression of cardiac hypertrophy and heart failure in vivo. J. Transl. Med. 2015, 13, 363. [CrossRef] [PubMed]

41. Li, C.; Li, X.; Gao, X.; Zhang, R.; Zhang, Y.; Liang, H.; Xu, C.; Du, W.; Zhang, Y.; Liu, X.; et al. MicroRNA-328 as a regulator of cardiac hypertrophy. Int. J. Cardiol. 2014, 173, 268–276. [CrossRef] [PubMed]

42. Ge, Y.; Pan, S.; Guan, D.; Yin, H.; Fan, Y.; Liu, J.; Zhang, S.; Zhang, H.; Feng, L.; Wang, Y.; et al. MicroRNA-350 induces pathological heart hypertrophy by repressing both p38 and JNK pathways. Biochim. Biophys. Acta 2013, 1832, 1–10. [CrossRef] [PubMed]

43. Elia, L.; Contu, R.; Quintavalle, M.; Varrone, F.; Chimenti, C.; Russo, M.A.; Cimino, V.; de Marinis, L.; Frustaci, A.; Catalucci, D.; et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 2009, 120, 2377–2385. [CrossRef] [PubMed]

44. Hua, Y.; Zhang, Y.; Ren, J. IGF-1 deficiency resists cardiac hypertrophy and myocardial contractile dysfunction: Role of microRNA-1 and microRNA-133a. J. Cell. Mol. Med. 2012, 16, 83–95. [CrossRef] [PubMed]

45. Varrone, F.; Gargano, B.; Carullo, P.; di Silvestre, D.; de Palma, A.; Grasso, L.; di Somma, C.; Mauri, P.; Benazzi, L.; Franzone, A.; et al. The circulating level of FABP3 is an indirect biomarker of microRNA-1. J. Am. Coll. Cardiol. 2013, 61, 88–95. [CrossRef] [PubMed]

46. Wang, Y.S.; Zhou, J.; Hong, K.; Cheng, X.S.; Li, Y.G. MicroRNA-223 displays a protective role against β-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS ONE 2012, 7, e42316. [CrossRef] [PubMed]

47. Thum, T.; Gross, C.; Fiedler, J.; Fischer, T.; Kessler, S.; Bussen, M.; Galuppo, P.; Just, S.; Rottbauer, W.; Frantz, S.; et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456, 980–984. [CrossRef] [PubMed]

48. Roy, S.; Khanna, S.; Hussain, S.R.; Biswas, S.; Azad, A.; Rink, C.; Gnyawali, S.; Shilo, S.; Nuovo, G.J.; Sen, C.K. MicroRNA expression in response to murine myocardial infarction: MiR-21 regulates fibroblast metalloprotease-2 via phosphate and tensin homologue. Cardiovasc. Res. 2009, 82, 21–29. [CrossRef] [PubMed]
Manzoni, G.M.; Castelnuovo, G.; Prioretti, R. Assessment of psychosocial risk factors is missing in the 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults. *J. Am. Coll. Cardiol.* 2011, 57, 1569–1570. [CrossRef] [PubMed]

Van Rooij, E.; Sutherland, L.B.; Thatcher, J.E.; DiMaio, J.M.; Naseem, R.H.; Marshall, W.S.; Hill, J.A.; Olson, E.N. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. *Proc. Natl. Acad. Sci. USA* 2008, 105, 13027–13032. [CrossRef] [PubMed]

Zhang, Y.; Huang, X.R.; Wei, L.H.; Chung, A.C.; Yu, C.M.; Lan, H.Y. miR-29b as a therapeutic agent for ischemia reperfusion injury. *Mol. Ther.* 2014, 22, 974–985. [CrossRef] [PubMed]

He, B.; Xiao, J.; Ren, A.J.; Zhang, Y.F.; Zhang, H.; Chen, M.; Xie, B.; Gao, X.G.; Wang, Y.W. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. *J. Biomed. Sci.* 2011, 18, 22. [CrossRef] [PubMed]

Wei, C.; Kim, I.K.; Kumar, S.; Jayasinghe, S.; Hong, N.; Castoldi, G.; Catalucci, D.; Jones, W.K.; Gupta, S. NF-xB mediated miR-26a regulation in cardiac fibrosis. *J. Cell. Physiol.* 2013, 228, 1433–1442. [CrossRef] [PubMed]

Wang, X.; Wang, H.X.; Li, Y.L.; Zhang, C.C.; Zhou, C.Y.; Wang, L.; Xia, Y.L.; Du, J.; Li, H.H. MicroRNA Let-7i negatively regulates cardiac inflammation and fibrosis. *Hypertension* 2015, 66, 776–785. [CrossRef] [PubMed]

Matkovich, S.; Wang, W.; Tu, Y.; Eschenbacher, W.H.; Dorn, L.E.; Condorelli, G.; Diwan, A.; Nerbonne, J.M.; Dorn, G.W. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. *Circ. Res.* 2010, 106, 166–175. [CrossRef] [PubMed]

Castoldi, G.; di Gioia, C.R.; Bombardi, C.; Catalucci, D.; Corradi, B.; Gualazzi, M.G.; Leopizzi, M.; Mancini, M.; Zerbini, G.; Condorelli, G.; et al. MiR-133a regulates collagen 1A1: Potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. *J. Cell. Physiol.* 2012, 227, 850–856. [CrossRef] [PubMed]

Pan, Z.; Sun, X.; Shan, H.; Wang, N.; Wang, J.; Ren, J.; Feng, S.; Xie, L.; Lu, C.; Yuan, Y.; et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway. *Circulation* 2012, 126, 840–850. [CrossRef] [PubMed]

Zhao, X.; Wang, K.; Liao, Y.; Zeng, Q.; Li, Y.; Hu, F.; Liu, Y.; Meng, K.; Qian, C.; Zhang, Q.; et al. MicroRNA-101a inhibits cardiac fibrosis induced by hypoxia via targeting TGFβRI on cardiac fibroblasts. *Cell. Physiol. Biochem.* 2015, 35, 213–226. [CrossRef] [PubMed]

Nagpal, V.; Rai, R.; Place, A.T.; Murphy, S.B.; Verma, S.K.; Ghosh, A.K.; Vaughan, D.E. MiR-125b is critical for fibroblast-to-myofibroblast transition and cardiac fibrosis. *Circulation* 2016, 133, 291–301. [CrossRef] [PubMed]

Wang, J.; Huang, W.; Xu, R.; Nie, Y.; Cao, X.; Meng, J.; Xu, X.; Hu, S.; Zheng, Z. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. *J. Cell. Mol. Med.* 2012, 16, 2150–2160. [CrossRef] [PubMed]

Duisters, R.F.; Tijsen, A.J.; Schroen, B.; Leenders, J.J.; Lintink, V.; van der Made, I.; Herias, V.; van Leeuwen, R.E.; Schellings, M.W.; Barenbrug, P.; et al. miR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. *Circ. Res.* 2009, 104, 170–178. [CrossRef] [PubMed]

Muraoka, N.; Yamakawa, H.; Miyamoto, K.; Sadahiro, T.; Umei, T.; Isomi, M.; Nakashima, H.; Akiyama, M.; Wada, R.; Inagawa, K.; et al. MiR-133 promotes cardiac reprogramming by directly repressing Snail1 and silencing fibroblast signatures. *EMBO J.* 2014, 33, 1565–1581. [CrossRef] [PubMed]

Elmore, S. Apoptosis: A review of programmed cell death. *Toxicol. Pathol.* 2007, 35, 495–516. [CrossRef] [PubMed]

Xu, C.; Hu, Y.; Hou, L.; Ju, J.; Li, X.; Du, N.; Guan, X.; Liu, Z.; Zhang, T.; Qin, W.; et al. β-Blocker carvedilol protects cardiomyocytes against oxidative stress-induced apoptosis by up-regulating miR-133 expression. *J. Mol. Cell. Cardiol.* 2014, 75, 111–121. [CrossRef] [PubMed]

Volk, N.; Paul, E.D.; Haramati, S.; Eitan, C.; Fields, B.K.; Zwang, R.; Gil, S.; Lowry, C.A.; Chen, A. MicroRNA-19b associates with Ago2 in the amygdala following chronic stress and regulates the adrenergic receptor β1. *J. Neurosci.* 2014, 34, 15070–15082. [CrossRef] [PubMed]

Fang, J.; Song, X.W.; Tian, J.; Chen, H.Y.; Li, D.F.; Wang, J.F.; Ren, A.J.; Yuan, W.J.; Lin, L. Overexpression of microRNA-378 attenuates ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes. *Apoptosis* 2012, 17, 410–423. [CrossRef] [PubMed]

He, B.; Xiao, J.; Ren, A.J.; Zhang, Y.F.; Zhang, H.; Chen, M.; Xie, B.; Gao, X.G.; Wang, Y.W. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. *J. Biomed. Sci.* 2011, 18, 22. [CrossRef] [PubMed]
68. Tang, Y.; Zheng, J.; Sun, Y.; Wu, Z.; Liu, Z.; Huang, G. MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. *Int. Heart J.* **2009**, *50*, 377–387. [CrossRef] [PubMed]

69. Liu, L.; Zhang, G.; Liang, Z.; Liu, X.; Li, T.; Fan, J.; Bai, J.; Wang, Y. MicroRNA-15b enhances hypoxia/reoxygenation-induced apoptosis of cardiomyocytes via a mitochondrial apoptotic pathway. *Apoptosis* **2014**, *19*, 19–29. [CrossRef] [PubMed]

70. Wei, C.; Li, L.; Gupta, S. NF-κB-mediated miR-30b regulation in cardiomyocytes cell death by targeting Bcl-2. *Mol. Cell. Biochem.* **2014**, *387*, 135–141. [CrossRef] [PubMed]

71. Zhao, F.; Li, B.; Wei, Y.Z.; Zhou, B.; Wang, H.; Chen, M.; Gan, X.D.; Wang, Z.H.; Xiong, S.X. MicroRNA-34a regulates high glucose-induced apoptosis in H9c2 cardiomyocytes. *J. Huazhong Univ. Sci. Technol. Med. Sci.* **2013**, *33*, 834–839. [CrossRef] [PubMed]

72. Li, X.; Zeng, Z.; Li, Q.; Xu, Q.; Xie, J.; Hao, H.; Luo, G.; Liao, W.; Bin, J.; Huang, X.; et al. Inhibition of microRNA-497 ameliorates anoxia/reoxygenation injury in cardiomyocytes by suppressing cell apoptosis and enhancing autophagy. *Oncotarget* **2015**, *6*, 18829–18844. [CrossRef] [PubMed]

73. Ding, S.L.; Wang, J.X.; Jiao, J.Q.; Tu, X.; Wang, Q.; Liu, F.; Li, Q.; Gao, J.; Zhou, Q.Y.; Gu, D.F.; et al. A pre-microRNA-149 (miR-149) genetic variation affects miR-149 maturation and its ability to regulate the Puma protein in apoptosis. *J. Biol. Chem.* **2013**, *288*, 26865–26877. [CrossRef] [PubMed]

74. Qian, L.; van Laake, L.W.; Huang, Y.; Liu, S.; Wendland, M.F.; Srivastava, D. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. *J. Exp. Med.* **2011**, *208*, 549–560. [CrossRef] [PubMed]

75. Yu, X.Y.; Song, Y.H.; Geng, Y.J.; Lin, Q.X.; Shan, Z.X.; Lin, S.G.; Li, Y. Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1. *Biochem. Biophys. Res. Commun.* **2008**, *376*, 548–552. [CrossRef] [PubMed]

76. Pan, Z.; Sun, X.; Ren, J.; Li, X.; Gao, X.; Lu, C.; Zhang, Y.; Sun, H.; Wang, Y.; Wang, H.; et al. miR-1 exacerbates cardiac ischemia-reperfusion injury in mouse models. *PLoS ONE* **2012**, *7*, e50515. [CrossRef] [PubMed]

77. Ren, X.P.; Wu, J.; Wang, X.; Sartor, M.A.; Qian, J.; Jones, K.; Nicolaou, P.; Pritchard, T.J.; Fan, G.C. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. *Circulation* **2009**, *119*, 2357–2366. [CrossRef] [PubMed]

78. Wei, C.; Li, L.; Kim, I.K.; Sun, P.; Gupta, S. NF-κB mediated miR-21 regulation in cardiomyocytes apoptosis under oxidative stress. *Free Radic. Res.* **2014**, *48*, 282–291. [CrossRef] [PubMed]

79. Cheng, Y.; Liu, X.; Zhang, S.; Lin, Y.; Yang, J.; Zhang, C. MicroRNA-21 protects against the H(2)O(2)-induced apoptosis of cardiac myocytes via its target gene PDCD4. *J. Mol. Cell. Cardiol.* **2009**, *47*, 5–14. [CrossRef] [PubMed]

80. Yang, Q.; Yang, K.; Li, A. microRNA-21 protects against ischemia-reperfusion and hypoxia-reperfusion-induced cardiocyte apoptosis via the phosphatase and tensin homolog/Akt-dependent mechanism. *Mol. Med. Rep.* **2014**, *9*, 2213–2220. [CrossRef] [PubMed]

81. Rane, S.; He, M.; Sayed, D.; Vashistha, H.; Malhotra, A.; Sadashima, J.; Vatner, D.E.; Vatner, S.F.; Abdellatif, M. Downregulation of miR-199a derepresses hypoxia-inducible factor-1α and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. *Circ. Res.* **2009**, *104*, 879–886. [CrossRef] [PubMed]

82. Li, J.; Donath, S.; Li, Y.; Qin, D.; Prabhakar, B.S.; Li, P. miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. *PLoS Genet.* **2010**, *6*, e1000795. [CrossRef] [PubMed]

83. Roca-Alonso, L.; Castellano, L.; Mills, A.; Dabrowska, A.F.; Sikkel, M.B.; Pellegrino, L.; Jacob, J.; Frampton, A.E.; Krell, J.; Coombs, R.C.; et al. Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis. *Cell Death Dis.* **2015**, *6*, e1754. [CrossRef] [PubMed]

84. Chen, A.; Li, G.; Chen, L.; Guo, J.; Liu, Y. Downregulation of microRNA-100 protects H2O2-induced apoptosis in neonatal cardiomyocytes. *Int. J. Clin. Exp. Pathol.* **2015**, *8*, 5491–5496. [PubMed]

85. Wu, D.; Jiang, H.; Chen, S.; Zhang, H. Inhibition of microRNA-101 attenuates hypoxia/reoxygenation-induced apoptosis through induction of autophagy in H9c2 cardiomyocytes. *Mol. Med. Rep.* **2015**, *11*, 3988–3994. [PubMed]

86. Hong, S.; Lee, J.; Seo, H.H.; Lee, C.Y.; Yoo, K.J.; Kim, S.M.; Lee, S.; Hwang, K.C.; Choi, E. Na+-Ca2+ exchanger targeting miR-132 prevents apoptosis of cardiomyocytes under hypoxic condition by suppressing Ca2+ overload. *Biochem. Biophys. Res. Commun.* **2015**, *460*, 931–937. [CrossRef] [PubMed]
87. Frank, D.; Gantenberg, J.; Boomgaard, I.; Kuhn, C.; Will, R.; Jarr, K.U.; Eden, M.; Kramer, K.; Luedde, M.; Mairbaurl, H.; et al. MicroRNA-20a inhibits stress-induced cardiomyocyte apoptosis involving its novel target Egln3/PHD3. J. Mol. Cell. Cardiol. 2012, 52, 711–717. [CrossRef] [PubMed]
88. Zhang, B.; Zhou, M.; Li, C.; Zhou, J.; Li, H.; Zhu, D.; Wang, Z.; Chen, A.; Zhao, Q. MicroRNA-92a inhibition attenuates hypoxia/reoxygenation-induced myocardioocyte apoptosis by targeting Smad7. PLoS ONE 2014, 9, e100298. [CrossRef] [PubMed]
89. Pfeffer, M.A.; Claggett, B.; Assmann, S.F.; Boineau, R.; Anand, I.S.; Clausell, N.; Desai, A.S.; Diaz, R.; Fleg, J.L.; Gordeev, I.; et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015, 131, 34–42. [CrossRef] [PubMed]
90. He, S.; Liu, P.; Jian, Z.; Li, J.; Zhu, Y.; Feng, Z.; Xiao, Y. miR-138 protects cardiomyocytes from hypoxia-induced apoptosis via MLK3/JNK/c-jun pathway. Biochem. Biophys. Res. Commun. 2013, 441, 763–769. [CrossRef] [PubMed]
91. Wong, L.L.; Wee, A.S.; Lim, J.Y.; Ng, J.Y.; Chong, J.P.; Liew, O.W.; Lilyanna, S.; Martinez, E.C.; Ackers-Johnson, M.A.; Vardy, L.A.; et al. Essential versus accessory aspects of cell death: Recommendations of the NCCD 2015. Cell Death Differ. 2015, 22, 58–73. [CrossRef] [PubMed]
92. Liu, Y.; Nie, H.; Zhang, K.; Ma, D.; Yang, G.; Zheng, Z.; Liu, K.; Yu, B.; Zhai, C.; Yang, S. A feedback regulatory loop between HIF-1α and miR-21 in response to hypoxia in cardiomyocytes. FEBS Lett. 2014, 588, 3137–3146. [CrossRef] [PubMed]
93. Galluzzi, L.; Bravo-San Pedro, J.M.; Vitale, I.; Aaronson, S.A.; Abrams, J.M.; Adam, D.; Alnemri, E.S.; Altucci, L.; Andrews, D.; Annicchiarico-Petruzzelli, M.; et al. Essential versus accessory aspects of cell death: Recommendations of the NCCD 2015. Cell Death Differ. 2015, 22, 58–73. [CrossRef] [PubMed]
94. Cha, M.J.; Jang, J.K.; Ham, O.; Song, B.W.; Lee, S.Y.; Lee, C.Y.; Park, J.H.; Lee, J.; Seo, H.H.; Choi, E.; et al. MicroRNA-145 suppresses ROS-induced Ca2+ overload of cardiomyocytes by targeting CaMKIIdelta. Biochem. Biophys. Res. Commun. 2013, 435, 720–726. [CrossRef] [PubMed]
95. Aurora, A.B.; Mahmoud, A.I.; Luo, X.; Johnson, B.A.; van Rooij, E.; Humphries, K.M.; Hill, J.A.; Bassel-Duby, R.; Sadek, H.A.; et al. MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca2+ overload and cell death. J. Clin. Invest. 2012, 122, 1222–1232. [CrossRef] [PubMed]
96. Pan, L.; Huang, B.J.; Ma, X.E.; Wang, S.Y.; Feng, J.; Lv, F.; Liu, Y.; Liu, Y.; Li, C.M.; Liang, D.D.; et al. miR-25 protects cardiomyocytes against oxidative damage by targeting the mitochondrial calcium uniporter. Int. J. Mol. Sci. 2015, 16, 5420–5433. [CrossRef] [PubMed]
97. Song, S.; Seo, H.H.; Lee, S.Y.; Lee, C.Y.; Lee, J.; Yoo, K.J.; Yoon, C.; Choi, E.; Hwang, K.C.; Lee, S. MicroRNA-17-mediated down-regulation of apoptotic protease activating factor 1 attenuates apoptosome formation and subsequent apoptosis of cardiomyocytes. Biochem. Biophys. Res. Commun. 2015, 465, 299–304. [CrossRef] [PubMed]
98. Yu, M.; Liu, Y.; Zhang, B.; Shi, Y.; Cui, L.; Zhao, X. Inhibiting microRNA-144 abates oxidative stress and reduces apoptosis in hearts of streptozotocin-induced diabetic mice. Cardiovasc. Pathol. 2015, 24, 375–381. [CrossRef] [PubMed]
99. Li, R.; Yan, G.; Li, Q.; Sun, H.; Hu, Y.; Sun, J.; Xu, B. MicroRNA-145 protects cardiomyocytes against hydrogen peroxide (H2O2)-induced apoptosis through targeting the mitochondria apoptotic pathway. PLoS ONE 2012, 7, e49407. [CrossRef] [PubMed]
100. Kim, J.O.; Kwon, E.J.; Song, D.W.; Lee, J.S.; Kim, D.H. miR-185 inhibits endoplasmic reticulum stress-induced apoptosis by targeting Na+/H+ exchanger-1 in the heart. BMB Rep. 2016, 49, 208–213. [PubMed]
101. Sayed, D.; He, M.; Hong, C.; Gao, S.; Rane, S.; Yang, Z.; Abdellatif, M. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J. Biol. Chem. 2010, 285, 20281–20290. [CrossRef] [PubMed]
102. Wang, X.; Zhang, X.; Ren, X.P.; Chen, J.; Liu, H.; Yang, J.; Medvedovic, M.; Hu, Z.; Fan, G.C. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation 2010, 122, 1308–1318. [CrossRef] [PubMed]
103. Wang, J.; Jia, Z.; Zhang, C.; Sun, M.; Wang, W.; Chen, P.; Ma, K.; Zhang, Y.; Li, X.; Zhou, C. miR-499 protects cardiomyocytes from H2O2-induced apoptosis via its effects on Pdcd4 and Pacs2. RNA Biol. 2014, 11, 339–350. [CrossRef] [PubMed]
104. Li, X.; Wang, J.; Jia, Z.; Cui, Q.; Zhang, C.; Wang, W.; Chen, P.; Ma, K.; Zhou, C. MiR-499 regulates cell proliferation and apoptosis during late-stage cardiac differentiation via Sox6 and cyclin D1. *PLoS ONE* 2013, 8, e74504. [CrossRef] [PubMed]
105. Zhang, W.G.; Chen, L.; Dong, Q.; He, J.; Zhao, H.D.; Li, F.L.; Li, H. Mmu-miR-702 functions as an anti-apoptotic mirtron by mediating ATF6 inhibition in mice. *Gene* 2013, 531, 235–242. [CrossRef] [PubMed]
106. Long, B.; Wang, K.; Li, N.; Murtaza, I.; Xiao, J.Y.; Fan, Y.Y.; Liu, C.Y.; Li, W.H.; Cheng, Z.; Li, P. miR-761 regulates the mitochondrial network by targeting mitochondrial fission factor. *Free Radic. Biol. Med.* 2013, 65, 371–379. [CrossRef] [PubMed]
107. Li, B.; Li, R.; Zhang, C.; Bian, H.J.; Wang, F.; Xiao, J.; Liu, S.W.; Yi, W.; Zhang, M.X.; Wang, S.X.; et al. MicroRNA-7a/b protects against cardiac myocyte injury in ischemia/reperfusion by targeting poly(ADP-ribose) polymerase. *PLoS ONE* 2014, 9, e90096. [CrossRef] [PubMed]
108. Li, J.; Li, Y.; Jiao, J.; Wang, J.; Li, Y.; Qin, D.; Li, P. Mitofusin 1 is negatively regulated by microRNA 140 in cardiomyocyte apoptosis. *Mol. Cell. Biol.* 2014, 34, 1788–1799. [CrossRef] [PubMed]
109. Du, W.; Pan, Z.; Chen, X.; Wang, L.; Zhang, Y.; Li, S.; Liang, H.; Xu, C.; Zhang, Y.; Wu, Y.; et al. By targeting Stat3 microRNA-17–5p promotes cardiomyocyte apoptosis in response to ischemia followed by reperfusion. *Cell. Physiol. Biochem.* 2014, 39, 955–965. [CrossRef] [PubMed]
110. Wang, L.; Huang, H.; Fan, Y.; Kong, B.; Hu, H.; Hu, K.; Guo, J.; Mei, Y.; Liu, W.L. Effects of downregulation of microRNA-181a on H2O2-induced H9c2 cell apoptosis via the mitochondrial apoptotic pathway. *Oxid. Med. Cell. Longev.* 2014, 2014, 960362. [CrossRef] [PubMed]
111. Zhu, H.; Yang, Y.; Wang, Y.; Li, J.; Schiller, P.W.; Peng, T. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. *Cardiovasc. Res.* 2011, 92, 75–84. [CrossRef] [PubMed]
112. Mutharasan, R.K.; Nagpal, V.; Ichikawa, Y.; Ardehali, H. microRNA-210 is upregulated in hypoxic cardiomyocytes. *Am. J. Physiol. Heart Circ. Physiol.* 2011, 301, H1519–H1530. [CrossRef] [PubMed]
113. Suh, J.H.; Choi, E.; Cha, M.J.; Song, B.W.; Ham, O.; Lee, S.Y.; Yoon, C.; Lee, C.Y.; Park, J.H.; Lee, S.H.; et al. Up-regulation of miR-26a promotes apoptosis of hypoxic rat neonatal cardiomyocytes by repressing GSK-3β protein expression. *Biochem. Biophys. Res. Commun.* 2012, 423, 404–410. [CrossRef] [PubMed]
114. Li, X.; Du, N.; Zhang, Q.; Li, J.; Chen, X.; Liu, X.; Hu, Y.; Qin, W.; Shen, N.; Xu, C.; et al. MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy. *Cell Death Dis.* 2014, 5, e1479. [CrossRef] [PubMed]
115. Fan, F.; Sun, A.; Zhao, H.; Liu, X.; Zhang, W.; Jin, X.; Wang, C.; Ma, X.; Shen, C.; Zou, Y.; et al. MicroRNA-34a promotes cardiomyocyte apoptosis post myocardial infarction through down-regulating aldehyde dehydrogenase 2. *Curr. Pharm. Des.* 2013, 19, 4865–4873. [CrossRef] [PubMed]
116. Wang, K.; Long, B.; Zhou, L.Y.; Liu, F.; Zhou, Q.Y.; Liu, C.Y.; Fan, Y.Y.; Li, P.F. CARL IncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation. *Nat. Commun.* 2014, 5, 3596. [CrossRef] [PubMed]
117. Lai, K.B.; Sanderson, J.E.; Izzat, M.B.; Yu, C.M. Micro-RNA and mRNA myocardial tissue expression in biopsy specimen from patients with heart failure. *Int. J. Cardiol.* 2015, 199, 79–83. [CrossRef] [PubMed]
118. Naga Prasad, S.V.; Duan, Z.H.; Gupta, M.K.; Surampudi, V.S.; Volinia, S.; Calin, G.A.; Liu, C.G.; Kotwal, A.; Moravec, C.S.; Starling, R.C.; et al. Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. *J. Biol. Chem.* 2009, 284, 27487–27499. [CrossRef] [PubMed]
119. Goren, Y.; Kushnir, M.; Zaffir, B.; Tabak, S.; Lewis, B.S.; Amir, O. Serum levels of microRNAs in patients with heart failure. *Eur. J. Heart Fail.* 2012, 14, 147–154. [CrossRef] [PubMed]
120. Ellis, K.L.; Cameron, V.A.; Troughton, R.W.; Frampton, C.M.; Ellmers, L.J.; Richards, A.M. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. *Eur. J. Heart Fail.* 2013, 15, 1138–1147. [CrossRef] [PubMed]
121. Watson, C.J.; Gupta, S.K.; O’Connell, E.; Thum, S.; Glezneva, N.; Hendrich, J.; Gallacher, J.; Ledwidge, M.; Grote-Levi, L.; McDonald, K.; et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. *Eur. J. Heart Fail.* 2015, 17, 405–415. [CrossRef] [PubMed]
122. Zhang, R.; Niu, H.; Ban, T.; Xu, L.; Li, Y.; Wang, N.; Sun, L.; Ai, J.; Yang, B. Elevated plasma microRNA-1 predicts heart failure after acute myocardial infarction. *Int. J. Cardiol.* 2013, 166, 259–260. [CrossRef] [PubMed]
123. Matsumoto, S.; Sakata, Y.; Suna, S.; Nakatani, D.; Usami, M.; Hara, M.; Kitamura, T.; Hamasaki, T.; Nanto, S.; Kawahara, Y.; et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. *Circ. Res.* 2013, 113, 322–326. [CrossRef] [PubMed]

124. Gidlof, O.; Smith, J.G.; Miyazu, K.; Gilje, P.; Spencer, A.; Blomquist, S.; Erlinge, D. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. *BMC Cardiovasc. Disord.* 2013, 13, 12. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).